EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Safety and efficacy of JWATM204, a novel glypican-3 (GPC3)-targeted chimeric antigen receptor (CAR) T-cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study

Yongqiang Yang, Jing Tang, Zilong Wu, Jinfeng Zhang, Dongen Liu, Jun Fan, Gang Wu, Tao Zhang, Jun Xue

Cancer Pathogenesis and Therapy · 2026-07 · 4 (4) · 297-309

DOI: 10.1016/j.cpt.2025.12.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Pathogenesis and Therapy, 2026-07. Verfasst von Yongqiang Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Xisike Clinical Oncology Research Foundation, Science Fund for Distinguished Young Scholars of Hubei Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

CAR T cell therapyGlypican-3Hepatocellular carcinomaImmunotherapySafety

Autor:innen und Institutionen

  • Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
  • Institute of Radiation Oncology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.
  • Hubei Key Laboratory of Precision Radiation Oncology, Wuhan, Hubei 430022, China.
  • Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, China.

Förderung

  • Beijing Xisike Clinical Oncology Research Foundation
  • Science Fund for Distinguished Young Scholars of Hubei Province
  • National Natural Science Foundation of China
  • Key Project of Research and Development Plan of Hunan Province

Zitieren

APA

Yang, Y., Tang, J., Wu, Z., Zhang, J., Liu, D., Fan, J., Wu, G., Zhang, T., & Xue, J. (2026). Safety and efficacy of JWATM204, a novel glypican-3 (GPC3)-targeted chimeric antigen receptor (CAR) T-cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study. Cancer Pathogenesis and Therapy, 4(4), 297-309. https://doi.org/10.1016/j.cpt.2025.12.002

Vancouver

Yang Y, Tang J, Wu Z, Zhang J, Liu D, Fan J, et al. Safety and efficacy of JWATM204, a novel glypican-3 (GPC3)-targeted chimeric antigen receptor (CAR) T-cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study. Cancer Pathogenesis and Therapy. 2026;4(4):297-309. doi:10.1016/j.cpt.2025.12.002

BibTeX
@article{Yang2026,
  author = {Yang, Yongqiang and Tang, Jing and Wu, Zilong and Zhang, Jinfeng and Liu, Dongen and Fan, Jun and Wu, Gang and Zhang, Tao and Xue, Jun},
  title = {Safety and efficacy of JWATM204, a novel glypican-3 (GPC3)-targeted chimeric antigen receptor (CAR) T-cell therapy for advanced hepatocellular carcinoma: A phase I dose-escalation study},
  journal = {Cancer Pathogenesis and Therapy},
  year = {2026},
  volume = {4},
  number = {4},
  pages = {297--309},
  doi = {10.1016/j.cpt.2025.12.002}
}
Kostenlos starten →